Spruce Biosciences to Participate in May Investor Conferences

Rhea-AI Summary

Spruce Biosciences (NASDAQ: SPRB) announced its participation in two upcoming investor conferences in May 2022. The first event is the RBC Capital Markets Global Healthcare Conference on May 17-18, featuring a fireside chat on May 17 at 10:00 a.m. ET. The second event is the H.C. Wainwright Global Investment Conference from May 23-26, with a company presentation on May 25 at 4:00 p.m. ET. Interested investors can access webcasts via the company’s investor relations website. Spruce focuses on therapies for rare endocrine disorders.

SAN FRANCISCO--(BUSINESS WIRE)-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that company management will participate in two upcoming investor conferences taking place in May.

• RBC Capital Markets Global Healthcare Conference
  Date: May 17-18, 2022
  Format: Fireside chat (May 17 at 10:00 a.m. ET) and 1x1 meetings

• H.C. Wainwright Global Investment Conference
  Date: May 23-26, 2022
  Format: Company presentation (May 25 at 4:00 p.m. ET) and 1x1 meetings

Interested parties can access the webcast for each conference presentation from the Events section of the company’s investor relations website at https://investors.sprucebiosciences.com. A replay of the webcasts will be available after the conclusion of the live presentations for approximately 30 days.

About Spruce Biosciences

Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). Classic CAH is a serious and life-threatening disease with no known novel therapies approved in approximately 50 years. Spruce is also developing tildacerfont for women suffering from polycystic ovary syndrome (PCOS) with primary adrenal androgen excess. To learn more, visit www.sprucebiosciences.com and follow us on Twitter @Spruce_Bio, LinkedIn, Facebook and YouTube.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220503005051/en/

Media Contact

Will Zasadny

Canale Communications

(619) 961-8848

will.zasadny@canalecomm.com

media@sprucebiosciences.com

Investors

Xuan Yang

Solebury Trout

(415) 971-9412

xyang@soleburytrout.com

investors@sprucebiosciences.com

Source: Spruce Biosciences, Inc.

FAQ

What investor conferences will Spruce Biosciences participate in May 2022?

Spruce Biosciences will participate in the RBC Capital Markets Global Healthcare Conference on May 17-18 and the H.C. Wainwright Global Investment Conference on May 23-26, 2022.

When is the fireside chat for Spruce Biosciences at the RBC Conference?

The fireside chat for Spruce Biosciences at the RBC Capital Markets Global Healthcare Conference is scheduled for May 17, 2022, at 10:00 a.m. ET.

When will Spruce Biosciences present at the H.C. Wainwright Conference?

Spruce Biosciences will present at the H.C. Wainwright Global Investment Conference on May 25, 2022, at 4:00 p.m. ET.

Where can I access the webcasts for Spruce Biosciences' presentations?

The webcasts for Spruce Biosciences' presentations can be accessed from the Events section of their investor relations website.

What is the focus of Spruce Biosciences' product candidates?

Spruce Biosciences focuses on developing therapies for rare endocrine disorders, specifically targeting conditions like congenital adrenal hyperplasia and polycystic ovary syndrome.